

CITATION REPORT

List of articles citing

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis

DOI: 10.1634/theoncologist.2016-0455
Oncologist, 2017, 22, 694-699.

Source: <https://exaly.com/paper-pdf/67600054/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Medication overuse in oncology: current trends and future implications for patients and society. <i>Lancet Oncology, The</i> , 2018 , 19, e200-e208	21.7	15
20	Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. <i>European Urology</i> , 2018 , 74, 57-62	10.2	33
19	Anti-Angiogenics: Their Value in Colorectal Cancer Therapy. <i>Oncology Research and Treatment</i> , 2018 , 41, 188-193	2.8	27
18	Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2018 , 38, 5539-5546	2.3	7
17	Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e294-e299	3.8	5
16	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. <i>Pharmacoeconomics</i> , 2020 , 38, 1263-1275	4.4	2
15	How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3283-3286	1.9	
14	The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating. <i>Pharmacoeconomics</i> , 2020 , 38, 737-745	4.4	4
13	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020 , 38, 683-713	4.4	5
12	Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project. <i>Cancers</i> , 2020 , 12,	6.6	6
11	Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. <i>MDM Policy and Practice</i> , 2021 , 6, 23814683211021060	1.5	2
10	Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. <i>Applied Health Economics and Health Policy</i> , 2021 , 19, 605-618	3.4	4
9	Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics. <i>Current Oncology Reports</i> , 2021 , 23, 31	6.3	6
8	Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. <i>Cancers</i> , 2021 , 13,	6.6	7
7	Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. <i>Molecular Diagnosis and Therapy</i> , 2021 , 25, 715-734	4.5	1
6	Comparative pharmacoeconomic analysis of metastatic colorectal cancer treatment. <i>Vestnik of Russian Military Medical Academy</i> , 2021 , 23, 213-220	0.3	
5	A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa.. <i>Applied Health Economics and Health Policy</i> , 2021 , 1	3.4	0

4	CLINICAL AND ECONOMIC JUSTIFICATION OF SOFTWARE SCREENING PERFORMANCE OF COLORECTAL CANCER AT THE REGION LEVEL. <i>Farmatsiya I Farmakologiya</i> , 2021 , 9, 465-475	0.6	
3	Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors.. <i>Frontiers in Oncology</i> , 2021 , 11, 692005	5.3	
2	Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer. <i>Clinical Colorectal Cancer</i> , 2022 ,	3.8	2
1	Overall Survival and Progression-Free Survival Comparison of Bevacizumab Plus Chemotherapy Combination Regimen versus Chemotherapy Only Regimen in Previously Untreated Metastatic Colorectal Cancer: Systematic Review and Meta-Analysis. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022 , 10, 269-277	1	